This phenomenon is well established clinically: for example, the most frequent adverse event associated with ibrutinib, atrial fibrillation, is attributed to off-target inhibition of cardiac kinases rather than to BTK blockade itself [21]. Here, BTK is linked to atrial fibrillation.